55,840 Zoetis Inc. $ZTS Shares Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 48.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 172,115 shares of the company’s stock after acquiring an additional 55,840 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Zoetis were worth $12,019,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Physician Wealth Advisors Inc. increased its stake in Zoetis by 17.4% in the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after buying an additional 91 shares in the last quarter. Lipe & Dalton lifted its holdings in shares of Zoetis by 2.2% in the 1st quarter. Lipe & Dalton now owns 4,698 shares of the company’s stock valued at $555,000 after acquiring an additional 102 shares during the last quarter. Root Financial Partners LLC lifted its stake in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. Rexford Capital Inc. boosted its stake in Zoetis by 5.3% during the first quarter. Rexford Capital Inc. now owns 2,352 shares of the company’s stock worth $278,000 after buying an additional 118 shares during the period. Finally, Valmark Advisers Inc. grew its holdings in Zoetis by 7.7% during the 1st quarter. Valmark Advisers Inc. now owns 1,747 shares of the company’s stock valued at $207,000 after purchasing an additional 125 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on ZTS shares. UBS Group upped their price objective on Zoetis from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Tuesday. Stifel Nicolaus lowered their target price on Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a report on Thursday, August 20th. Weiss Ratings reiterated a “sell (d)” rating on shares of Zoetis in a research note on Wednesday, September 9th. TD Cowen cut their price objective on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. lowered their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $98.40.

Zoetis Stock Performance

ZTS opened at $78.25 on Wednesday. The company has a 50-day moving average price of $74.84 and a 200 day moving average price of $94.35. Zoetis Inc. has a twelve month low of $68.77 and a twelve month high of $147.46.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.15 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be issued a dividend of $0.53 per share. The ex-dividend date is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%.

Zoetis Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.